Background: Many studies reported a renal protection by sodium glucose cotransporter-2 inhibitor (SGLT2i) using in
Type 2 diabetes mellitus (T2DM). Objective: Our study was designed to evaluate the renal benefit offered by SGLT2
inhibitor (dapagliflozin) in type 2 diabetic patients. Patients and Methods: 100 diabetic patients, 50 treated by
dapagliflozin 10 mg once daily for 12 months and 50 treated by placebo for the same period. Patients were recruited
from those attending Endocrinology Unit in Benha University Hospital. Clinical and laboratory data were performed to
patients who were followed up every 3 months for 1 year. Results: No significant difference among the two groups
regarding age, sex, residence, and the common adverse effects. Urinary albumin/creatinine ratio was statistically lower
in SGLT2i group compared to placebo group at the end of the study but was non-significant at base line. Estimated
glomerular filtration rate (eGFR) was statistically higher in SGLT2i group compared to placebo group at the end of the
study although there was non-significant difference at base line. No significant difference between the two groups
regarding HbA1c at base line, 3 and 6 months later but was statistically lower in SGLT2i group after 9 months and 1
year. BMI, SBP and DBP were statistically lower in SGLT2i group at the end of the study but there was non-significant
difference at base line. Conclusion: We found reno protective properties by using sodium glucose cotransporter-2
inhibitor (dapagliflozin) in type 2 diabetic patients, a great impact on glycemic control and other pleiotropic effects
without significant differences regarding common adverse effects. |
